Home  /  Resource Library  /  Nivolumab treatment followed by consolidation with allo-HSCT is associated with favorable outcomes in patients with relapsed/refractory Hodgkin lymphoma

Nivolumab treatment followed by consolidation with allo-HSCT is associated with favorable outcomes in patients with relapsed/refractory Hodgkin lymphoma

Results of a retrospective study examining the effectiveness of Nivolumab on stem cell transplant in patients with relapsed Hodgkin lymphoma.